Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BID | P55957 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28871108 | 0.98 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL260553 | 0.85 | CES2 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28566012 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3117223 | 0.83 | CES2 (0.64) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL7968059 | 0.83 | CES2 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5603402 | 0.83 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL224031 | 0.83 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8130379 | 0.82 | TTR (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31263802 | 0.82 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8921906 | 0.80 | CA1 (0.94) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092029-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | SCRIPPS RESEARCH INST (US) | 2026-04-02 | — | — | US | claimed |
| EP-4584236-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | The Scripps Research Institute (US) | 2025-07-16 | — | — | EP | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117796401-A | Preparation process of 2-hydroxy-6-fluorobenzoic acid methyl ester-containing intermediate antibacterial agent | 江苏万隆化学有限公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2024054881-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-14 | — | — | WO | claimed |
| CN-113736232-B | Modified biodegradable material and preparation method thereof | 万华化学（宁波）有限公司 | 2023-07-14 | — | — | CN | claimed |
| US-11400102-B2 | Treatment for bacterial infections with salicylic acid analogs | WASHINGTON UNIVERSITY (US) | 2022-08-02 | — | — | US | claimed |
| CN-113816940-A | Nicotine salts, co-crystals and salt co-crystal complexes | R.J.雷诺兹烟草公司 | 2021-12-21 | — | — | CN | claimed |
| CN-113754634-A | Nicotine salts, co-crystals and salt co-crystal complexes | R.J.雷诺兹烟草公司 | 2021-12-07 | — | — | CN | claimed |
| CN-113736232-A | Modified biodegradable material and preparation method thereof | 万华化学（宁波）有限公司 | 2021-12-03 | — | — | CN | claimed |
| US-20200368256-A1 | Treatment for Bacterial Infections | WASHINGTON UNIVERSITY (US) | 2020-11-26 | — | — | US | claimed |
| CN-106336352-A | Synthesis method of 6-fluorosalicylic acid | 扬州天辰精细化工有限公司 | 2017-01-18 | — | — | CN | claimed |
| CN-102320960-A | Preparation method of 6-fluoro salicylic acid | ANHUI DONGJIAN CHEMICAL INDUSTRY CO LTD | 2012-01-18 | — | — | CN | claimed |
| WO-2005021581-A2 | INDUCERS OF PLANT DISEASE RESISTANCE | VALENT BIOSCIENCES CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050050587-A1 | Inducers of plant disease resistance | VALENT BIOSCIENCES CORPORATION | 2005-03-03 | — | — | US | claimed |
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | RAI STRATEGIC HOLDINGS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-5300640-A | Herbicide intermediates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5125957-A | Pre- and postemergence herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0426476-A1 | Pyrimidine derivatives, their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260107971-A1 | AEROSOL GENERATING MATERIAL IN DISCRETE PORTIONS COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, CHRM1 | CA12 2583/4885CA1 2910/4885CA2 1318/4885 |
| US-20260092029-A1 | LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE | CYP2B6, CYP2A6, CYP1A1 | CA12 1761/4885CA1 430/4885CA2 179/4885 |
| US-20200368256-A1 | Treatment for Bacterial Infections | BPGM, BLVRB, LRBA | CA12 3111/4885CA1 3512/4885CA2 2998/4885 |
| US-20260107968-A1 | END PLUG COMPRISING A SUBSTITUTED 3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | ALK, EXOSC4, EXOSC9 | CA12 4013/4885CA1 4122/4885CA2 3788/4885 |
| US-11400102-B2 | Treatment for bacterial infections with salicylic acid analogs | BPGM, LRBA, LTC4S | CA12 3217/4885CA1 3643/4885CA2 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.